A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective Response Rate in subjects with Breast cancer
1 year
Helen Eliopoulos, MD
Study Director
Abbott
United States: Food and Drug Administration
M02-447
NCT00063102
November 2002
August 2004
Name | Location |
---|---|
Oncology-Hematology Group of South Florida | Miami, Florida 33176 |
Georgia Cancer Specialists | Decatur, Georgia 30033 |
Texas Oncology | Dallas, Texas |
Clinical Research Network, Inc. | Plantation, Florida 33324 |
Northwestern University Medical School Division of Hematology/Oncology | Chicago, Illinois 60611 |
Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion | Indianapolis, Indiana 46202 |
Northern Indiana Cancer Research Consortium | South Bend, Indiana |
Oncology & Hemotology Associates of Kansas City, PA | Kansas City, Missouri 64111 |